In the second-biggest M&A deal so far in 2023, Biogen Inc. plans to acquire Reata Pharmaceuticals Inc. for an enterprise value of about $7.3 billion. Read More

Investors will have to wait for durability of response (DoR) data from Urogen Pharma Ltd.’s phase III Envision study with UGN-102 (mitomycin intravesical solution) in low-grade, intermediate-risk, non-muscle invasive bladder cancer, but urologists already characterize what’s available so far from that study, as well as Atlas – another late-stage experiment – as practice-changing. Read More

Broadly neutralizing antibodies (bNAbs) have the potential to prevent HIV, and more researchers are turning to bNAbs as an alternative to antiretroviral therapy (ART), speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia. Read More

Hangzhou and New Jersey-based cancer biotech Adlai Nortye Ltd. – formerly Hangzhou Nuotai Pharmaceutical Co. Ltd. – announced plans to list on Nasdaq with its U.S. IPO filed on July 27. Read More

The radiopharmaceuticals field is gaining traction as companies realize that by harnessing the power of radioactive atoms, they can create targeted and more effective cancer drugs which cause less damage to healthy tissues. As a result, competition for a place as a leading radiopharma firm is high, and the market is estimated to reach $11.5 billion by 2027. Read More

Clinical data in the first half of 2023 is up 1.51% compared to the same time period last year. So far in 2023 BioWorld reported on 1,810 drugs in phase I-III, compared to 1,783 in the first half of 2022. The number of trial updates is down 13.6% from the 2,095 in 2021, but more than 2020’s 1,799 and 2019’s 1,477. Read More

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019. Read More

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

New hires and promotions in the biopharma industry, including: Astrazeneca, Invivyd, Lexicon, Navidea, Okyo, Plus, Vaxxinity. Read More

Biopharmas raising money in public or private financings, including: Inozyme, Mendus, Tonix. Read More

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aquestive, Astrazeneca, Avenue, Checkpoint, Daiichi Sankyo, Disc, Eli Lilly, Eyepoint, Glyscend, Lipocine, Maat, Merck & Co., Mersana, Newamsterdam, Synthekine Takeda, Telavant, Tonix, Urogen. Read More

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alexion, Biontech, Evotec, Homology, Pfizer, Sanofi. Read More

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akari, Astrazeneca, Biohaven, Cessation, Defender, Jiangsu Recbio, Krystal, Precision. Read More